Making Progress on HCV Treatment in HIV-Infected Patients

Incivek Rash Reports: What HIV/Hepatitis C-Coinfected People Need to Know

Thu, 17 May 2012 09:10:00 GMT

As you know, certain drugs can sometimes cause a rash. Some of our readers may have had this experience with penicillin as a child. But despite the risk of a rash, we continue to use penicillin as an antibiotic because it is so valuable in curing bacterial infections, such as strep throat.

More News on Drug Interactions With New HCV Drugs -- This Time With Daclatasvir

Tue, 3 Apr 2012 10:28:00 GMT

Drug interactions are important because they can lead to levels that are either too high or too low. In light of these concerns, more drug companies are looking at potential hepatitis C (HCV) drug interactions with HIV medications.

Incivek Triple Therapy Looks Simply Great in HIV/HCV-Coinfected Patients

Wed, 28 Mar 2012 09:34:00 GMT

I have said for a long time that once we got some specially targeted hepatitis C (HCV) drugs, HIV/HCV-coinfected patients would finally have a great chance at an HCV cure. Well, the news from CROI 2012 seems to suggest just that.

Victrelis in the Spotlight for HIV/HCV-Coinfected Patients

Mon, 26 Mar 2012 10:33:00 GMT

News from the latest major HIV research conference continues to look great for hepatitis C (HCV) cures.

More results from a Victrelis (boceprevir) treatment trial were unveiled at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle, Wash. The researchers showed results of treatment 12 weeks after 95 HIV-infected patients with HCV genotype 1 infection had finished 48 weeks of treatment with either a) PEG interferon plus ribavirin plus placebo (i.e., dual therapy, which has been the standard of treatment for many years) or b) PEG interferon plus ribavirin plus Victrelis (i.e., triple therapy).

Making Sense of the Drug Interaction Warning for HIV/HCV-Coinfected Patients Taking Victrelis

Tue, 28 Feb 2012 11:16:00 GMT

In April of 2010, an advisory panel to the U.S. Food and Drug Administration (of which I am a member) urged approval of the hepatitis C (HCV) protease inhibitor Victrelis (boceprevir) for the treatment of patients with HCV infection. At the same time, we also requested more studies on drug interactions between Victrelis and HIV drugs in preparation for treatment studies in the HIV/HCV-coinfected patient.

Vitrelis (Boceprevir) in HIV/HCV-Coinfected Patients: A Look at Recent Research

Tue, 28 Feb 2012 11:15:00 GMT

The news about hepatitis C (HCV) treatment in the HIV-positive patient with genotype 1 infection continues to be exciting. As a reader of TheBody.com you have probably already seen my blog entry on the use of Incivek (telaprevir) with pegylated interferon (PEG) and ribavirin (RBV), which has some great early "on-treatment" results.

Incivek (Telaprevir) in HIV/HCV-Coinfected Patients: A Look at Recent Research

Mon, 6 Feb 2012 08:45:00 GMT

What a great year 2011 was for news about hepatitis C virus treatment! The last major meeting of the year featuring hepatitis research, the American Association for the Study of Liver Diseases (AASLD) meeting (referred to as the "Liver Meeting"), was filled with breathtaking data on what promises to be an amazing pipeline of new HCV drugs.

Looking Forward to a Bright New Year in HIV/HCV Treatment

Tue, 10 Jan 2012 08:45:00 GMT

As we discover a sense of renewal with the beginning of 2012, I find myself more hopeful than I have ever been regarding the outlook for patients with hepatitis C virus (HCV) infection, including patients coinfected with HIV.